Loss of VHL promotes progerin expression, leading to impaired p14/ARF function and suppression of p53 activity

References

• Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9:138 - 41; http://dx.doi.org/10.1016/0168-9525(93)90209-Z; PMID: 8516849
   PubMed Web of Science ®Google Scholar
• Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260:1317 - 20; http://dx.doi.org/10.1126/science.8493574; PMID: 8493574
   PubMed Web of Science ®Google Scholar
• Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome--a molecular and clinical review. Br J Cancer 1997; 76:1 - 14; http://dx.doi.org/10.1038/bjc.1997.328; PMID: 9218725
   PubMed Web of Science ®Google Scholar
• Feng Z, Hu W, Teresky AK, Hernando E, Cordon-Cardo C, Levine AJ. Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci USA 2007; 104:16633 - 8; http://dx.doi.org/10.1073/pnas.0708043104; PMID: 17921246
   PubMed Web of Science ®Google Scholar
• Delahunt B. Advances and controversies in grading and staging of renal cell carcinoma. Mod Pathol 2009; 22:Suppl 2 S24 - 36; http://dx.doi.org/10.1038/modpathol.2008.183; PMID: 19494851
   PubMedGoogle Scholar
• Gurova KV, Hill JE, Razorenova OV, Chumakov PM, Gudkov AV. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res 2004; 64:1951 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-03-1541; PMID: 15026329
   PubMed Web of Science ®Google Scholar
• Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7:85 - 90; http://dx.doi.org/10.1038/ng0594-85; PMID: 7915601
   PubMed Web of Science ®Google Scholar
• Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399:271 - 5; http://dx.doi.org/10.1038/20459; PMID: 10353251
   PubMed Web of Science ®Google Scholar
• Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997; 94:4273 - 8; http://dx.doi.org/10.1073/pnas.94.9.4273; PMID: 9113979
   PubMed Web of Science ®Google Scholar
• Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010; 40:294 - 309; http://dx.doi.org/10.1016/j.molcel.2010.09.022; PMID: 20965423
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353 - 64; http://dx.doi.org/10.1016/S0092-8674(00)80108-7; PMID: 8756718
   PubMed Web of Science ®Google Scholar
• Seagroves TN, Peacock DL, Liao D, Schwab LP, Krueger R, Handorf CR, et al. VHL deletion impairs mammary alveologenesis but is not sufficient for mammary tumorigenesis. Am J Pathol 2010; 176:2269 - 82; http://dx.doi.org/10.2353/ajpath.2010.090310; PMID: 20382704
   PubMed Web of Science ®Google Scholar
• Burtner CR, Murakami CJ, Kennedy BK, Kaeberlein M. A molecular mechanism of chronological aging in yeast. Cell Cycle 2009; 8:1256 - 70; http://dx.doi.org/10.4161/cc.8.8.8287; PMID: 19305133
   PubMed Web of Science ®Google Scholar
• Worman HJ, Fong LG, Muchir A, Young SG. Laminopathies and the long strange trip from basic cell biology to therapy. J Clin Invest 2009; 119:1825 - 36; http://dx.doi.org/10.1172/JCI37679; PMID: 19587457
   PubMed Web of Science ®Google Scholar
• De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, et al. Lamin a truncation in Hutchinson-Gilford progeria. Science 2003; 300:2055; http://dx.doi.org/10.1126/science.1084125; PMID: 12702809
   PubMed Web of Science ®Google Scholar
• Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003; 423:293 - 8; http://dx.doi.org/10.1038/nature01629; PMID: 12714972
   PubMed Web of Science ®Google Scholar
• Scaffidi P, Misteli T. Lamin A-dependent nuclear defects in human aging. Science 2006; 312:1059 - 63; http://dx.doi.org/10.1126/science.1127168; PMID: 16645051
   PubMed Web of Science ®Google Scholar
• Scaffidi P, Misteli T. Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med 2005; 11:440 - 5; http://dx.doi.org/10.1038/nm1204; PMID: 15750600
   PubMed Web of Science ®Google Scholar
• Voorhoeve PM, Agami R. The tumor-suppressive functions of the human INK4A locus. Cancer Cell 2003; 4:311 - 9; http://dx.doi.org/10.1016/S1535-6108(03)00223-X; PMID: 14585358
   PubMed Web of Science ®Google Scholar
• Burtner CR, Kennedy BK. Progeria syndromes and ageing: what is the connection?. Nat Rev Mol Cell Biol 2010; 11:567 - 78; http://dx.doi.org/10.1038/nrm2944; PMID: 20651707
   PubMed Web of Science ®Google Scholar
• Bertout JA, Majmundar AJ, Gordan JD, Lam JC, Ditsworth D, Keith B, et al. HIF2α inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci USA 2009; 106:14391 - 6; http://dx.doi.org/10.1073/pnas.0907357106; PMID: 19706526
   PubMed Web of Science ®Google Scholar
• Frew IJ, Krek W. Multitasking by pVHL in tumour suppression. Curr Opin Cell Biol 2007; 19:685 - 90; http://dx.doi.org/10.1016/j.ceb.2007.10.001; PMID: 18006292
   PubMed Web of Science ®Google Scholar
• Roberts AM, Watson IR, Evans AJ, Foster DA, Irwin MS, Ohh M. Suppression of hypoxia-inducible factor 2α restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res 2009; 69:9056 - 64; http://dx.doi.org/10.1158/0008-5472.CAN-09-1770; PMID: 19920202
   PubMed Web of Science ®Google Scholar
• Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 1999; 13:1822 - 33; http://dx.doi.org/10.1101/gad.13.14.1822; PMID: 10421634
   PubMed Web of Science ®Google Scholar
• Jung YS, Lee SJ, Yoon MH, Ha NC, Park BJ. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions. Cell Cycle 2012; 11:4462 - 73; http://dx.doi.org/10.4161/cc.22794; PMID: 23159849
   PubMed Web of Science ®Google Scholar
• Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004; 429:86 - 92; http://dx.doi.org/10.1038/nature02514; PMID: 15103385
   PubMed Web of Science ®Google Scholar
• Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69:1237 - 45; http://dx.doi.org/10.1016/0092-8674(92)90644-R; PMID: 1535557
   PubMed Web of Science ®Google Scholar
• Nikolaev AY, Li M, Puskas N, Qin J, Gu W. Parc: a cytoplasmic anchor for p53. Cell 2003; 112:29 - 40; http://dx.doi.org/10.1016/S0092-8674(02)01255-2; PMID: 12526791
   PubMed Web of Science ®Google Scholar
• Al-Mulla F, Hagan S, Behbehani AI, Bitar MS, George SS, Going JJ, et al. Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J Clin Oncol 2006; 24:5672 - 9; http://dx.doi.org/10.1200/JCO.2006.07.5499; PMID: 17179102
   PubMed Web of Science ®Google Scholar
• Sükösd F, Kuroda N, Beothe T, Kaur AP, Kovacs G. Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma. Cancer Res 2003; 63:455 - 7; PMID: 12543802
   PubMed Web of Science ®Google Scholar
• Roe JS, Kim H, Lee SM, Kim ST, Cho EJ, Youn HD. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 2006; 22:395 - 405; http://dx.doi.org/10.1016/j.molcel.2006.04.006; PMID: 16678111
   PubMed Web of Science ®Google Scholar
• Blander G, Zalle N, Leal JF, Bar-Or RL, Yu CE, Oren M. The Werner syndrome protein contributes to induction of p53 by DNA damage. FASEB J 2000; 14:2138 - 40; PMID: 11023999
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844 - 8; http://dx.doi.org/10.1126/science.1092472; PMID: 14704432
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92:725 - 34; http://dx.doi.org/10.1016/S0092-8674(00)81401-4; PMID: 9529249
   PubMed Web of Science ®Google Scholar
• Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998; 95:8292 - 7; http://dx.doi.org/10.1073/pnas.95.14.8292; PMID: 9653180
   PubMed Web of Science ®Google Scholar
• Rodway H, Llanos S, Rowe J, Peters G. Stability of nucleolar versus non-nucleolar forms of human p14(ARF). Oncogene 2004; 23:6186 - 92; http://dx.doi.org/10.1038/sj.onc.1207854; PMID: 15286709
   PubMed Web of Science ®Google Scholar
• Brynes RK, Golomb HM, Desser RK, Recant W, Reese C, Rowley J. Acute monocytic leukemia. Cytologic, histologic, cytochemical, ultrastructural, and cytogenetic observations. Am J Clin Pathol 1976; 65:471 - 82; PMID: 57715
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876 - 80; http://dx.doi.org/10.1126/science.1062538; PMID: 11423618
   PubMed Web of Science ®Google Scholar
• Tang Y, Chen Y, Jiang H, Nie D. Promotion of tumor development in prostate cancer by progerin. Cancer Cell Int 2010; 10:47; http://dx.doi.org/10.1186/1475-2867-10-47; PMID: 21106101
   PubMed Web of Science ®Google Scholar
• Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999; 5:1164 - 70; http://dx.doi.org/10.1038/13495; PMID: 10502820
   PubMed Web of Science ®Google Scholar
• Dunham MA, Neumann AA, Fasching CL, Reddel RR. Telomere maintenance by recombination in human cells. Nat Genet 2000; 26:447 - 50; http://dx.doi.org/10.1038/82586; PMID: 11101843
   PubMed Web of Science ®Google Scholar
• Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009; 10:992 - 1000; http://dx.doi.org/10.1016/S1470-2045(09)70240-2; PMID: 19796751
   PubMed Web of Science ®Google Scholar
• Meek DW. Tumour suppression by p53: a role for the DNA damage response?. Nat Rev Cancer 2009; 9:714 - 23; PMID: 19730431
   PubMed Web of Science ®Google Scholar
• Kudlow BA, Stanfel MN, Burtner CR, Johnston ED, Kennedy BK. Suppression of proliferative defects associated with processing-defective lamin A mutants by hTERT or inactivation of p53. Mol Biol Cell 2008; 19:5238 - 48; http://dx.doi.org/10.1091/mbc.E08-05-0492; PMID: 18843043
   PubMed Web of Science ®Google Scholar
• Liu B, Wang J, Chan KM, Tjia WM, Deng W, Guan X, et al. Genomic instability in laminopathy-based premature aging. Nat Med 2005; 11:780 - 5; http://dx.doi.org/10.1038/nm1266; PMID: 15980864
   PubMed Web of Science ®Google Scholar
• O’Neill M, Núñez F, Melton DW. p53 and a human premature ageing disorder. Mech Ageing Dev 2003; 124:599 - 603; http://dx.doi.org/10.1016/S0047-6374(03)00007-1; PMID: 12735900
   PubMed Web of Science ®Google Scholar
• Mack FA, Rathmell WK, Arsham AM, Gnarra J, Keith B, Simon MC. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 2003; 3:75 - 88; http://dx.doi.org/10.1016/S1535-6108(02)00240-4; PMID: 12559177
   PubMed Web of Science ®Google Scholar
• Artacho-Pérula E, Roldán-Villalobos R, Blanco-García F, Blanco-Rodríguez A. Objective differential classification of thyroid lesions by nuclear quantitative assessment. Histol Histopathol 1997; 12:425 - 31; PMID: 9151131
   PubMed Web of Science ®Google Scholar
• Fenner A. Prostate cancer. Nuclear irregularity is a predictor of clinical outcome. Nat Rev Urol 2010; 7:475; http://dx.doi.org/10.1038/nrurol.2010.131; PMID: 20839382
   PubMedGoogle Scholar
• Swerdlow SH, Pelstring RJ, Collins RD. Morphometric analysis of follicular center cell lymphomas. Am J Pathol 1990; 137:953 - 63; PMID: 2221019
   PubMed Web of Science ®Google Scholar
• Fong LG, Frost D, Meta M, Qiao X, Yang SH, Coffinier C, et al. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 2006; 311:1621 - 3; http://dx.doi.org/10.1126/science.1124875; PMID: 16484451
   PubMed Web of Science ®Google Scholar